Oral Session 1-13A Conditioning Regimens (1)

[OS1-13A-3] The effect of melphalan dose as reduced-intensity conditioning for acute lymphoblastic leukemia

Kaito Harada¹, Takayoshi Tachibana², Kazuteru Ohashi³, Yukiyasu Ozawa⁴, Masashi Sawa⁵, Tadakazu Kondo⁶, Jun Ishikawa⁷, Makoto Onizuka¹, Kazunori Imada⁸, Tomoaki Fujisaki⁹, Junji Tanaka¹⁰, Takahiro Fukuda¹¹, Yoshiko Atsuta^12,13, Shinichi Kako¹⁴ (1.Department of Hematology and Oncology, Tokai University, Isehara, Japan, 2.Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan, 3.Hematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 4.Department of Hematology, Japanese Red Cross Nagoya First Hospital, 5.Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan, 6.Department of Hematology, Kyoto University Hospital, Kyoto, Japan, 7.Department of Hematology, Osaka International Cancer Institute, Osaka, Japan, 8.Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan, 9.Department of Internal Medicine, Matsuyama Red Cross Hospital, Matsuyama, Japan, 10.Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan, 11.Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, 12.Japanese Data Center for Hematopoietic Cell Transplantation, 13.Department of Healthcare Administration, Nagoya University, Nagoya, Japan, 14.Division of Hematology, Jichi University, Saitama Medical Center, Saitama, Japan)